A comparison of two commercial adamts13 activity ASSAYS with a reference laboratory method

Laboratory Medicine

Volumn 40, Issue 4, 2009, Pages 232-235

  Crist, Ronda A ^a   Rodgers, George M ^b  

^a ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSIS, MEASUREMENT AND ANALYSIS; DIAGNOSTIC PROCEDURE; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 70349377146     PISSN: 00075027     EISSN: None     Source Type: Journal    
DOI: 10.1309/LM95OQN0GLZPYHBP     Document Type: Article

References (5)

1. Lammle B, Kremer Hovinga JA, Alberio L. Thrombotic thrombocytopenic purpura. J Thromb Haemost. 2005;3:1663-1675.
2. Furlan M, Robles R, Galbusera M, et al. Von Willebrand factor cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Eng J Med. 1998;339:1578-1584. (Pubitemid 28536132)
3. Zhou W, Tsai HM. An enzyme immunoassay of ADAMTS13 distinguishes patients with thrombotic thrombocytopenic purpura from normal individuals and carriers of ADAMTS13 mutations. Thromb Haemost. 2004;91:806-811.
4. Kokame K, Nobe Y, Kokubo Y, et al. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol. 2005;129:93-100.
5. Kremer Hovinga JA, Mottini M, Lammle B. Measurement of ADAMTS-13 activity in plasma by the FRETS-VWF73 assay: Comparison with other assay methods. J Thromb Haemost. 2006;4:1146-1148.